Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    20385792 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: dexamethasone
2 Withdrawn Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
3 Active, not recruiting Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone

Study has passed its completion date and status has not been verified in more than two years.